Age-related macular degeneration (AMD) is the fourth biggest cause of visual impairment. Early diagnosis and treatment with intravitreal injections of anti-VEGF drugs saves sight. The burden of such treatments may be challenging to patients and carers and may reduce adherence to therapy. Investigations of alternative therapeutic targets and modalities are providing promising results. New drugs are being developed that require fewer treatments, thereby improving treatment efficacy and reducing disease burden.
Modern Medicine – Oct/Nov 2018